IP Library › Granted Patent US 7,282,588
Granted Patent B2
US 7,282,588 · App. 11/612,531 · Granted Oct 16, 2007

Azaindole inhibitors of aurora kinases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,282,588
App. No.
11/612,531
Granted
Oct 16, 2007
Kind
B2
Abstract

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

Claims (1)

1. A compound which is N′-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Jan 6, 2010
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 023731/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2007
From: DHANAK, DASHYANT; NEWLANDER, KENNETH ALLEN
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 018704/0352 →